The emerging role of the selective A2A agonist in pharmacologic stress testing

Journal of Nuclear Cardiology

Volumn 17, Issue 3, 2010, Pages 494-497

  Gemignani, Anthony S ^a   Abbott, Brian G ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE PHOSPHATE; AMINOPHYLLINE; APADENOSON; BINODENOSON; CAFFEINE; DIPYRIDAMOLE; PLACEBO; REGADENOSON; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ANGINA PECTORIS; ASTHMA; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATRIOVENTRICULAR BLOCK; BOLUS INJECTION; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DIZZINESS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; EXERCISE TEST; FALSE NEGATIVE RESULT; FLUSHING; HEART BLOCK; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEAT SENSATION; HUMAN; HYPEREMIA; IMAGE QUALITY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MYOCARDIAL PERFUSION IMAGING; NAUSEA; NONHUMAN; PARESTHESIA; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT DEPRESSION; TACHYCARDIA; THORAX PAIN;

ANIMALS; CAFFEINE; EXERCISE; HUMANS; MYOCARDIAL PERFUSION IMAGING; PURINES; PYRAZOLES; RECEPTOR, ADENOSINE A2A; VASODILATION;

EID: 77953326814     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12350-010-9211-9     Document Type: Review

References (18)

1. MI Miyamoto SL Vernotico M Majmundar GS Thomas 2007 Pharmacologic stress myocardial perfusion imaging: A practice approach J Nuc Cardiol 14 250 255 10.1016/j.nuclcard.2007.01.006 (Pubitemid 46444679)
2. MD Cerqueira MS Verani M Schwaiger J Heo AS Iskandrian 1994 Safety profile of adenosine stress perfusion imaging: Results of the Adenoscan Multicenter Trial Registry JACC 23 2 384 389 1:STN:280:DyaK2c7isVyhuw%3D%3D 8294691
3. AE Iskandrian TM Bateman L Belardinelli B Blackburn MD Cerqueira RC Hendel, et al. 2007 Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial J Nuc Cardiol 14 645 658 10.1016/j.nuclcard.2007.06.114 (Pubitemid 47355078)
4. MD Cerqueira P Nguyen P Staehr SR Underwood AE Iskandrian 2008 Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist, regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results JACC Imaging 1 307 316 10.1016/j.jcmg.2008. 02.003 (Pubitemid 351676842)
5. JJ Mahmarian MD Cerqueira AE Iskandrian TM Bateman GS Thomas RC Hendel, et al. 2009 Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the advance MPI 2 trial JACC Imaging 2 959 968 10.1016/j.jcmg.2009.04.011
6. www.lexascan.com/home.php. Accessed February 24, 2010
7. C Mekkaoui F Jadbabaie DP Dione DF Meoli K Purushothaman L Belardinelli, et al. 2009 Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-SestaMIBI biodistribution and kinetics JACC Imaging 2 1198 1208 10.1016/j.jcmg.2009.06.013
8. HD Lieu JC Shryock GO von Mering T Gordi B Blackburn AW Olmsted, et al. 2007 Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans J Nuc Cardiol 14 514 520 10.1016/j.nuclcard.2007.02.016 (Pubitemid 47163555)
9. G Zhao E Messina X Xu M Ochoa HL Sun K Leung, et al. 2007 Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist J Cardiovasc Pharmacol 49 6 369 375 10.1097/FJC.0b013e318046f364 1:CAS:528:DC%2BD2sXmsFOisrc%3D 17577101 (Pubitemid 47000311)
10. O Gaemperli T Schepis P Koepfli PT Siegrist S Fleischman P Nguyen, et al. 2008 Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography a randomized, double-blind, placebo-controlled crossover trial J Am Coll Cardiol 51 328 329 10.1016/j.jacc.2007.10.014 18206744
11. H Samady FJ Wackers TM Joska BL Zaret D Jain 2002 Pharmacologic stress perfusion imaging with adenosine: Role of simultaneous low-level treadmill exercise J Nuc Card 9 2 188 196 10.1067/mnc.2002.119973
12. TA Holly A Satran DS Bromet JH Mieres MJ Frey MD Elliott, et al. 2003 The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the Both Exercise and Adenosine Stress Test (BEAST) trial J Nuc Card 10 3 291 296 10.1016/S1071-3581(02)43236-9 (Pubitemid 36758074)
13. GS Thomas RC Thompson MI Miyamoto TK Ip DL Rice D Milikien, et al. 2009 The RegEx trial: A randomized, double-blind, placebo- and active- controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging J Nuc Card 16 1 63 72 10.1007/s12350-008-9001-9
14. BR Leaker B O'Connor TT Hansel PJ Barnes L Meng VS Mathur, et al. 2008 Safety of regadenoson, and adenosine A2A agonist for myocardial perfusion imaging, in mild asthma patients: A randomized, double-blind, placebo-controlled trial J Nuc Card 15 3 329 336 10.1016/j.nuclcard.2008.02.009
15. GS Thomas BR Tammelin GL Schiffman 2008 Safety of regadenoson, a selective A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial J Nuc Card 15 3 319 328 10.1016/j.nuclcard.2008.02.013
16. T Gordi B Blackburn H Lieu 2007 Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function J Clin Pharmacol 47 825 833 10.1177/0091270007301620 1:CAS:528:DC%2BD2sXot1GisbY%3D 17585115
17. S Laighold R Druz 2009 Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis J Nuc Card 16 478 480 10.1007/s12350-008-9043-z
18. W Al Jaroudi D Hermann F Hage 2010 Safety of Regadenoson in patients with End-Stage Renal Disease Am J Cardiol 105 133 135 10.1016/j.amjcard.2009.08.663 1:CAS:528:DC%2BD1MXhsFyitbvP